Clinical trial
PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC
NCT00313482 · Veeda Oncology, Other · Terminated
Key facts
| NCT number | NCT00313482 |
|---|---|
| Title | PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC |
| Official title | A Phase II Trial of Docetaxel/Prednisone in Combination With Sargramostim as Treatment for Hormone-refractory Prostate Cancer |
| Lead sponsor | Veeda Oncology, Other |
| Collaborators | Bayer Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hormone Refractory Prostate Cancer |
| Intervention type | Drug |
| Interventions | Sargramostim, Docetaxel, Prednisone |
| Enrollment | 35 |
| Start date | Apr 1, 2006 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Apr 12, 2006 |
| Last update posted | May 11, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: